“The Nusantara vaccine will certainly continue to be promoted and is currently being given in hospitals. Of course, its usage is a bit different because it is a form of immunotherapy administered through medical equipment," the minister noted during an online press conference on Monday.
On the other hand, some of the Red and White Vaccines that entered the trial stage comprised the vaccine manufactured through collaboration between Airlangga University and Biotis and the vaccine produced by Baylor and State-owned Enterprises.
Related news: Nusantara vaccine can control coronavirus mutations: Professor
Hartarto also drew attention to the vaccination rate at the 2022 Moto GP location in West Nusa Tenggara, with a capacity to accommodate 64 thousand spectators. The rate of the second dose of COVID-19 vaccination in Mataram had reached 78 percent; West Lombok, 57.9 percent; Central Lombok, 61 percent; East Lombok, 57 percent; and North Lombok, 69 percent.
"The third dose of vaccination is expected to be administered in January, February, and March," Hartarto stated.
Furthermore, he noted that G20-related meetings would be resumed in January, such as several Sherpa Meetings, comprising Civil 20, Super Audit 20, Youth 20, Business Forum 20, Women 20, and Urban 20. The meetings will be conducted through virtual and in-person methods, he noted.
“The Finance Track will be conducted but entirely in a virtual manner. The government will issue a separate circular regarding the implementation of G20 that will regulate various activities," Hartarto remarked.
Coordinating Minister Airlangga expects the series of G20 activities to be executed in accordance with health protocols. Based on the Finance Track and Sherpa Track in December 2021, the participants were satisfied with the travel bubble policy imposed by Indonesia.
Related news: House backs Nusantara vaccine's phase three clinical trial: legislator
Translator: Kuntum Khaira R, Mecca Yumna
Editor: Suharto
Copyright © ANTARA 2022
